The Spectrum of Kidney Pathology in B-Cell Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma: A 25-Year Multicenter Experience
Anne-Laure Poitou-Verkinder, Arnaud François, Fanny Drieux, Stéphane Leprêtre, Bruno Legallicier, Bruno Moulin, Michel Godin, Dominique Guerrot

To cite this version:
Anne-Laure Poitou-Verkinder, Arnaud François, Fanny Drieux, Stéphane Leprêtre, Bruno Legallicier, et al.. The Spectrum of Kidney Pathology in B-Cell Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma: A 25-Year Multicenter Experience. PLoS ONE, Public Library of Science, 2015, 10 (3), pp.e0119156. 10.1371/journal.pone.0119156. hal-02317951

HAL Id: hal-02317951
https://hal-normandie-univ.archives-ouvertes.fr/hal-02317951
Submitted on 16 Oct 2019
RESEARCH ARTICLE

The Spectrum of Kidney Pathology in B-Cell Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma: A 25-Year Multicenter Experience

Anne-Laure Poitou-Verkinder1, Arnaud Francois2, Fanny Drieux2, Stéphane Lepretre3, Bruno Legalicier1, Bruno Moulin4, Michel Godin1,5, Dominique Guerrot1,5

1 Service de Néphrologie, CHU Hôpitaux de Rouen, Rouen, France, 2 Service d’Anatomie Pathologique, CHU Hôpitaux de Rouen, Rouen, France, 3 Service d’Hématologie, Centre Henri Becquerel, Rouen, France, 4 Service de Néphrologie, CHU Hôpitaux de Strasbourg, Strasbourg, France, 5 INSERM Unité 1096, Université de Médecine-Pharmacie de Rouen, Rouen, France

* dominique.guerrot@chu-rouen.fr

Abstract

Background

Chronic lymphocytic leukemia and small lymphocytic lymphoma are 2 different presentations of the most common B-cell neoplasm in western countries (CLL/SLL). In this disease, kidney involvement is usually silent, and is rarely reported in the literature. This study provides a clinicopathological analysis of all-cause kidney disease in CLL/SLL patients.

Methods

Fifteen CLL/SLL patients with kidney biopsy were identified retrospectively. Demographic, clinical, pathological and laboratory data were assessed at biopsy, and during follow-up.

Results

At biopsy 11 patients presented impaired renal function, 7 patients nephrotic syndrome, 6 patients dysproteinemia, and 3 patients cryoglobulinemia. Kidney pathology revealed CLL/SLL-specific monoclonal infiltrate in 10 biopsies, glomerulopathy in 9 biopsies (5 membranoproliferative glomerulonephritis, 2 minimal change disease, 1 glomerulonephritis with organized microtubular monoclonal immunoglobulin deposits, 1 AHL amyloidosis). Five patients presented interstitial granulomas attributed to CLL/SLL. After treatment of the hematological disease, improvement of renal function was observed in 7/11 patients, and remission of nephrotic syndrome in 5/7 patients. During follow-up, aggravation of the kidney disease systematically occurred in the absence of favorable response to hematological treatment.

Conclusions

A broad spectrum of kidney diseases is associated with CLL/SLL. In this setting, kidney biopsy can provide important information for diagnosis and therapeutic guidance.
Introduction

Kidney diseases are frequently associated with hematologic malignancies. Depending on the type and stage of the malignancy, the spectrum of kidney pathology can be particularly wide, including immune-mediated glomerulonephritis, interstitial monoclonal infiltration and tubular obstruction.

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are two different presentations of the most frequent B-cell neoplasm in adults in Western countries, with an annual incidence of 4–30 cases per 100,000 persons per year [1,2]. Although most patients remain asymptomatic, the clinical features of CLL/SLL are highly variable, including presentation, course and outcome. Unlike renal involvement in monoclonal gammapathies, the description of kidney diseases associated with CLL/SLL is currently limited to case reports and small series of immune-mediated glomerulopathies and interstitial infiltration by monoclonal lymphocytes [3–9].

In this context, the objective of the present study was to provide a systematic description of kidney pathology and clinical characteristics in a well characterized population of CLL/SLL patients referred for kidney biopsy, in order to better delineate the spectrum and the relative frequency of kidney diseases associated with CLL/SLL.

Subjects and Methods

Patients

This study included all the CLL/SLL patients who underwent a kidney biopsy in Haute-Normandie (1 800 000 inhabitants) between 1989 and 2014. During the study period, 3950 kidney biopsies were performed in the 8 hospitals and clinics of the region. All the biopsies were processed and analyzed in a single central reference pathology department, where the samples were systematically included in a tissue bank (Pathology Department, Rouen University Hospital, Rouen, France). Finally, after screening of the central patient database, 15 patients (20 biopsies) were included on the basis of a CLL/SLL diagnosis ascertained before or at the time of the kidney biopsy. Two of the 15 patients were reported in a previous study specifically focusing on glomerulonephritis in CLL/SLL [8]. Demographic, clinical and laboratory data, including results of the nephrological investigations prompting kidney biopsy, were recorded at time of the biopsy, and from the initial to the latest follow-up.

CLL/SLL was diagnosed according to the WHO classification (ICD-0 9823/3) [1,2]. An indicative extrapolation based on data from the Basse-Normandie CLL/SLL registry estimates that approximately 525 new cases of SLL and 2875 of CLL were diagnosed in Haute-Normandie over the 25-year study period. The diagnosis of CLL requires the presence of at least 5.10^9 B lymphocytes /l in the peripheral blood, over > 3 months, with evidence of monoclonality (CD5, CD19, CD20, CD23) [1,2]. CLL is distinguishable from SLL by its leukemic appearance. The definition of SLL requires a histological analysis of lymph node biopsy, and the clinical presentation includes lymphadenopathy and/or splenomegaly. In this case, lymph node histology shows small lymphocytes with condensed chromatin and, occasionally, small nucleolus. Large lymphoid cells with more prominent nucleoli and dispersed chromatin are typically present, and are usually clustered in pseudofollicles. The Binet staging system classifies CLL in stages A, B, or C according to the number of lymphoid tissues involved (enlarged lymph nodes in the neck, groin, underarms, hepatomegaly or splenomegaly), and to the presence of anemia and thrombocytopenia. Matutes score is based on the most common marker profile in CLL (CD5+, CD23+, FMC7- and weak surface immunoglobulin (SIg) and CD22), and is used to distinguish between typical (Matutes 4 and 5) and atypical CLL, by assigning scores that range
from 5 to 0 [10]. General signs were defined as A: no general sign; or B: weight loss > 10% in 6 months, and/or fever > 38°C without alternative diagnosis and/or nocturnal sweating. Tumoral syndrome was defined as the presence of lymphadenopathy and/or extrarenal organ infiltration (hepatomegaly, splenomegaly). Hematological response to treatment was defined according to the reference guidelines [1]. Dysproteinemias were identified by serum protein immuno electrophoresis and immunofixation.

Nephrotic syndrome (NS) was defined as proteinuria > 3 g/d with albuminemia < 30 g/l. Complete remission was defined as proteinuria < 0.3 g/d, partial remission as proteinuria < 3 g/d, and relapse as proteinuria > 3g/d after initial remission [11]. Acute renal failure was defined by an increase in plasma creatinine > 26.5 micromol/l and/or >150% baseline value, according to the Acute Kidney Injury Network (AKIN) criteria [12]. Kidney function improvement was defined as a decrease in plasma creatinine > 10%, with persistence > 3 months. Chronic kidney disease was defined as a decrease in MRDR eGFR < 90 ml/min/1.73 m² with persistence > 3 months [13].

Kidney pathology

The 20 biopsies were processed in a standardized manner in Rouen pathology department. Light microscopy analysis was performed after fixation in Dubosq Brazil solution, 2-μm paraffin section, and coloration by Masson trichrome, hematoxylin & eosin, Marizozzi silver, and Congo red stainings. Standardized immunofluorescence was performed retrospectively in 2014. 3-μm cryostat sections were incubated with FITC-conjugated antibodies to human Ig gamma, alpha, mu, kappa, and lambda light chains, C3, C4, C1q, fibrinogen, albumin, CD5, CD20, CD23, CD3, Cyclin D1 and CD10. The biopsies were reanalyzed in a blinded fashion by 2 experienced kidney and hematology pathologists. Ultrastructural electron microscopy was performed in 7 patients.

Ethical requirements

This study was in accordance with the Helsinki declaration, and was approved by the local ethics board for non-invasive health research (Comité d’Ethique pour la Recherche Non Interven tionnelle CERNI N°E-2014-11, for the Centre de Protection des Personnes Nord-Ouest-I, Rouen University Hospital, Rouen, France), which waived the need for informed consent in this retrospective analysis.

Results

Clinical presentation at kidney biopsy

The clinical features at biopsy are presented in Table 1. The CLL/SLL had been diagnosed before the nephropathy in 7/15 cases, with a mean interval of 61 months from the hematological to the nephrological diagnosis in this setting (range 19–156 months). General symptoms were present in 7/15 patients, and 11/15 patients presented lymphadenopathy, hepatomegaly, and/or splenomegaly. Extrarenal symptoms were present in 4/15 patients (peripheral neuropathy, arthralgia, skin vasculitis, cholestasis).

Laboratory and radiological data

In all patients, the kidney biopsy was performed because of renal failure and/or significant proteinuria. The laboratory and radiological results are presented in Tables 2 and 3. MDRD eGFR < 60 ml/min/1.73m² was found in 11/15 patients, (mean 23 ml/min/1.73m², range 7–38). NS was present in 7/15 patients, while normal proteinuria and urine sediment were
found in 2 cases. The hematological work-up revealed dysproteinemia in 6/15 patients (cases 4, 5, 10, 11, 12, 14), with cryoglobulinemia in 3 cases (cases 10, 11, 12). Complement activation was found in 5/15 patients (cases 9, 10, 11, 12, 13). Enlarged kidneys were noticed in one patient (case 6).

Pathology

Tables 4 and 5 summarize the conclusions of the kidney biopsy analyses. Monoclonal infiltration was evidenced in 10/15 biopsies. All of these 10 patients presented specific and abundant tumoral infiltration, which was generally associated with non specific reactive lymphocytes.
The common morphological feature in these cases was a diffuse nodular infiltration, composed of small mature lymphocytes, with small hyperchromatic nuclei, expanding the interstitium at the expense of the tubular structures, the peritubular capillaries, and less frequently the glomeruli (Fig. 1). Immunohistochemistry revealed monotypic lymphocytes (CD20+, CD5+, Cyclin D1-, CD10-). Six patients presented interstitial infiltration without glomerular lesions. Four had a severe infiltration, associated with GFR < 30 ml/min/1.73m², which represented the indication for kidney biopsy. There was no clear association between the intensity of interstitial infiltration, the CLL stage, and the acute vs chronic presentation of kidney failure. A tumoral syndrome was found in 9/10 of the patients with interstitial infiltration, compared to 2/5 patients without interstitial infiltration. Acute kidney injury was attributed to tubular necrosis in 2 patients (cases 6 and 9), and to interstitial infiltration in cases 2, 5, and 12. In the patients with AKI occurring in a context of MPGN, no extracapillary proliferation was found.

### Table 2. Laboratory and radiological features.

| Case | AKI/CKD | P. creatinine (micromol/l) | MDRD eGFR (ml/min) | Proteinuria (g/d) | P. albumin (g/l) | Hematuria | Leukocyturia | Dysproteinemia | Fanconi Syndrome | Complement | Kidney length (R/L, mm) |
|------|---------|-----------------------------|--------------------|-------------------|------------------|-----------|-------------|---------------|-----------------|-------------|------------------------|
| 1    | CKD     | 185 / 34                    | 0.3 / 56           | N                 | N                | N         | N           | N             | Normal          | 101 / 110    |                        |
| 2    | AKI     | 743 / 7                     | 1 / 39             | Y                 | Y                | N         | N           | N             | Normal          | 120 / 120    |                        |
| 3    | CKD     | 178 / 28                    | 0.9 / 43           | N                 | Y                | N         | N           | N             | Normal          | 120 / 120    |                        |
| 4    | CKD     | 194 / 36                    | 0.3 / 49           | N                 | Y                | N         | N           | IgG kappa 4.6 g/l / kappa BJ | Y           | Normal          | 120 / 107  |
| 5    | CKD     | 247 / 24                    | 0.8 / 44           | N                 | N                | N         | Lambda BJ  | N             | Normal          | 113 / 113    |                        |
| 5bis | AKI/CKD | 638 / 8                     | 1.4 / 41           | N                 | N                | Y         | N           | Y             | Normal          | Normal       |                        |
| 6    | AKI     | 616 / 8                     | 1.2 / 36           | Y                 | Y                | N         | N           | Normal         | Normal          | >120 / >120  |                        |

**Glomerular lesions associated or not with interstitial nephropathy**

| Case | AKI/CKD | P. creatinine (micromol/l) | MDRD eGFR (ml/min) | Proteinuria (g/d) | P. albumin (g/l) | Hematuria | Leukocyturia | Dysproteinemia | Fanconi Syndrome | Complement | Kidney length (R/L, mm) |
|------|---------|-----------------------------|--------------------|-------------------|------------------|-----------|-------------|---------------|-----------------|-------------|------------------------|
| 7    | CKD     | 193 / 38                    | 3.8 / 44           | Y                 | N                | N         | N           | N             | Normal          | 118 / 108    |                        |
| 8    | N       | 74 / 72                     | 6.1 / 20           | N                 | N                | N         | N           | N             | Normal          | Normal       |                        |
| 8bis | N       | 71 / 76                     | 4.6 / 32           | Y                 | N                | IgG lambda | N           | Normal         | Normal          | Normal       |                        |
| 9    | AKI     | 178 / 36                    | 6.3 / 21           | Y                 | N                | N         | N           | N             | Low C3          | Normal       |                        |
| 10   | N       | 71 / 75                     | 1.2 / 43           | Y                 | Y                | Type II cryoglobulin | N           | Low C3 and C4  | 117 / 112       | Normal         |                        |
| 10bis| CKD     | 96 / 53                     | 13 / 19            | Y                 | Y                | Type II cryoglobulin | N           | Low C3 and C4  | ND              | Normal         |                        |
| 11   | CKD     | 168 / 28                    | 14 / 25            | Y                 | Y                | Type I cryoglobulin, IgG kappa | N           | Low C3 and C4  | 103 / 108       | Normal         |                        |
| 12   | AKI/CKD | 536 / 7                     | >3 / 30            | Y                 | Y                | Type I cryoglobulin, IgG kappa | N           | Low C4         | 118 / 123       |                        |                        |
| 12bis| AKI/CKD | 769 / 5                     | 4.5 / 25           | Y                 | Y                | IgG kappa  | N           | Normal         | 95 / 95         | Normal       |                        |
| 13   | N       | 100 / 67                    | >6 / 24            | Y                 | Y                | N         | N           | N             | Low C3 and C4  | Normal       |                        |
| 14   | CKD     | 470 / 12                    | 7 / 24             | N                 | N                | IgG lambda | N           | ND             | Normal          | 116 / 100    |                        |
| 15   | N       | 79 / 67                     | 6.1 / 30           | Y                 | Y                | N         | N           | N             | Normal          | Normal       |                        |
| 15bis| CKD     | 530 / 7                     | >13 / 28           | Y                 | Y                | N         | N           | Normal         | Normal          | Normal       |                        |

AKI, acute kidney injury; CKD, chronic kidney disease; P, plasma; BJ, Bence Jones proteinuria; ND, no data available.

doi:10.1371/journal.pone.0119156.t002
Interstitial granulomas were found in 5/15 patients. Light microscopy revealed florid interstitial gigantocellular granulomas, surrounded by lymphocytes (Fig. 2). No tubular basement membrane rupture, cellular necrosis or microcrystalline precipitation was observed, and Periodic Acid Schiff, Ziehl and Grocott stainings revealed no microorganism. Immunofluorescence showed no specific interstitial deposit. Granulomas were a prominent feature in cases 4, 6 and on the 2nd biopsy of case 8. The granulomas were associated with monotypic interstitial infiltration (cases 4, 5, 6), or with glomerular deposits (cases 14, 15). No extrarenal granuloma was found in these patients.

Nine patients presented glomerular lesions, of which 4/9 were associated with monoclonal interstitial infiltration. Membranoproliferative glomerulonephritis (MPGN) was present in 5 patients (cases 9–13). Light microscopy revealed typical mesangial and/or endocapillary proliferation, double contours of the basement membrane, and endomembranous deposits (Fig. 3). The deposits were related to a circulating cryoglobulin in cases 10–12. In these 3 patients an important polymorphic infiltration with polymorphonuclear cells, lymphocytes and macrophages associated with endomembranous deposits was responsible for the formation of pseudothrombi in capillary loops, and fibrinoid deposits in one patient (case 10). The ultrastructural study revealed proliferative mesangial cells, podocyte foot process fusion, and endomembranous homogeneous granular deposits. The immunofluorescence confirmed the

| Case | Lymphocyte count (*/mm3) | Cytopenia (0;1;2) | Blood flow cytometry | Matutes | Bone marrow lymphocyte infiltration | Binet stage |
|------|--------------------------|------------------|----------------------|---------|------------------------------------|-------------|
| 1    | 16000                    | 0                | Lambda, CD5+ CD19+ CD23+ CD38- Smlg strong | 2       | 76%                                | A           |
| 2    | 70680                    | 2 (Hb,platelets) | Lambda, CD5+ CD19+ | ND      | 62%                                | C           |
| 3    | 1380                     | 0                | Kappa, CD5+ CD19+ CD23+ CD38- | 5       | ND                                 | B           |
| 4    | 102000                   | 1 (platelets)    | CD5+ CD19+ CD23+ FMC7- Smlg weak | 5       | 35%                                | B           |
| 5    | 102300                   | 1 (platelets)    | Lambda, CD5+ CD19+ CD23+ FMC7- CD38- | 5       | ND                                 | C           |
| 5bis | 7605                     | 2 (Hb, platelets) |                     | 5       | ND                                 | C           |
| 6    | 80170                    | 1 (Hb)           | CD5+ CD19+ CD23+ FMC7- CD38- CD79b weak Smlg weak | 5       | ND                                 | A           |

Glomerular lesions associated or not with interstitial nephropathy

| Case | Lymphocyte count (*/mm3) | Cytopenia (0;1;2) | Blood flow cytometry | Matutes | Bone marrow lymphocyte infiltration | Binet stage |
|------|--------------------------|------------------|----------------------|---------|------------------------------------|-------------|
| 7    | 27200                    | 0                | Kappa, CD5+ CD19+ CD23+ | 5       | ND                                 | A           |
| 8    | 36800                    | 0                | Lambda, CD5+ CD19+ Smlg weak | ND      | 75%                                | A           |
| 8bis | 8100                     | 0                |                     | ND      | ND                                 | A           |
| 9    | 3652                     | 1 (Hb)           | CD5+ CD19+ CD23+ CD38+ Smlg strong | /       | ND                                 | /           |
| 10   | 3250                     | 0                | Kappa, CD5+ CD19+ | ND      | 74%                                | A           |
| 10bis| 6960                     | 1 (Hb)           | Kappa, CD5+ CD19+ | ND      | ND                                 | ND          |
| 11   | 7691                     | 1 (Hb)           | Kappa, CD5+ CD19+ CD23- FMC7+ CD79b weak Smlg weak | /       | 82%                                | /           |
| 12   | 7100                     | 0                | Kappa, CD5+ CD19+ CD23 weak FMC7+ | ND      | 75%                                | B           |
| 12bis| 11590                    | 2 (Hb, platelets) |                     | ND      | 85%                                | C           |
| 13   | 10350                    | 1 (Hb: AIHA)     | ND                   | /       | 78%                                | /           |
| 14   | 7636                     | 0                | Lambda, CD5- CD19- Smlg strong | ND      | 37%                                | A           |
| 15   | 9870                     | 1 (Hb)           | Lambda, CD5+ CD19+ CD23+ Smlg weak | 5       | 49%                                | C           |
| 15bis| 1110                     | 1 (platelets)    |                     | 5       | 55%                                | C           |

AIHA, autoimmune hemolytic anemia; Smlg, surface membrane immunoglobulin; Hb, hemoglobin; ND, no data available.

doi:10.1371/journal.pone.0119156.t003
| Case | Light microscopy | Glomerular immunofluorescence | Infiltrate immunohistochemistry | Electron microscopy | Definite diagnosis |
|------|-----------------|------------------------------|-------------------------------|---------------------|------------------|
| 1    | Mild monomorphic diffuse infiltrate | Ig alpha Ig mu traces | CD20+ CD5+ CD23+ Cyclin D1- CD10- | | CLL infiltrate |
| 2    | Moderate monomorphic diffuse infiltrate | Normal | CD20+ CD5+ CD23+ CD10- Cyclin D1- | | CLL infiltrate |
| 3    | Moderate monomorphic focal infiltrate | Ig gamma Ig mu C3 C1q traces | CD20+ CD5+ CD23+ CD10- Cyclin D1- | | CLL infiltrate |
| 4    | Two monomorphic nodules | Normal | CD20+ CD5+ CD23- CD79a weak CD10- (nodules) | | CLL infiltrate Granulomatous reaction |

**Interstitial nephropathy: isolated specific tumoral interstitial infiltrate +/- CLL/SLL-related granulomatosis**

| 5    | One interstitial granuloma | ND | CD20+ CD5+ CD23+ CD10- Cyclin D1- | | CLL infiltrate Granulomatous reaction |

**Severe monomorphic diffuse infiltrate**

| 5bis | Abundant interstitial granulomas | Normal | CD20+ CD5+ CD23+ CD10- | | CLL infiltrate Granulomatous reaction |

**Glomerular lesions associated or not to interstitial nephropathy**

| 6    | Abundant epithelioid non-necrotic peritubular granulomas | Normal | CD20+ CD5+ CD79a+ CD23+ CD10- Cyclin D1- CD1- | | CLL infiltrate Granulomatous reaction |

**Severe monomorphic diffuse infiltrate**

| 7    | MCD | Ig mu C3 C4 C1q traces | CD20- CD3+ CD5+ CD19 CD23- Cyclin D1- | | MCD |

**Mild polymorphic diffuse infiltrate**

| 8    | MCD | ND | / | Foot process fusion | MCD |
| 8bis | MCD | Normal | / | | MCD |

| 9    | MPGN with capillary thrombi | Ig gamma Ig mu kappa lambda C4 C1q, C3 traces | CD20+ CD5+ CD23- Cyclin D1- (nodule) | Abundant subendothelial non-organized non-fibrillar deposits | MPGN |

**One monomorphic nodule, mild polymorphic infiltrate**

| 10   | MPGN with endocapillary proliferation | ND | / | Rare non-oriented cylindric 280-nm long 35-nm diameter deposits | Cryoglobulin-related MPGN |

| 10bis | MPGN with endocapillary proliferation and fibrinoid deposits | Ig gamma Ig alpha Ig mu C1q C3 C4 | / | | Cryoglobulin-related MPGN |

**Pseudo-thrombi**

| 11   | MPGN with endo- and extra-capillary proliferation | Ig gamma1 kappa C3, C1q traces | CD20+ CD5+ CD23+ CD10- fibrillar deposits | Subendothelial granular and fibrillar deposits | Cryoglobulin-related MPGN CLL infiltrate |

(Continued)
presence of the circulating cryoglobulin within glomerular deposits. Hepatitis B, C, and HIV serologies were negative in all patients. In patients 9 and 13 neither cryoglobulin nor dysproteinemia were detected. Case 13 presented monotypic gamma and kappa deposits together with positive C3 on immunofluorescence analysis, and decreased C3 and C4 in the peripheral blood tests. Large endomembranous deposits characterized by 8-nm diameter microfibrillar structures, organized in 0.96-μm long and 0.45-μm large bundles composed of approximately 12 elements were evidenced, leading to the diagnosis of fibrillary glomerulonephritis.

Patient 15 presented an immunotactoid glomerulonephritis with organized microtubular monoclonal immunoglobulin deposits. Light microscopy revealed mesangial sclerosis with focal mesangial proliferation (Fig. 4). Large globular deposits were observed in the capillary

### Table 4. (Continued)

| Case | Light microscopy | Glomerular immunofluorescence | Infiltrate immunohistochemistry | Electron microscopy | Definite diagnosis |
|------|------------------|------------------------------|-------------------------------|--------------------|-------------------|
| 15   | Mesangial sclerosis | Ig gamma lambda C3 | CD20+ CD5+ CD23- CD10- C3 | ND | ITGN |
|      | One interstitial granuloma |              | Subendothelial organized microtubular deposits | | |
|      | Mild monomorphic focal infiltrate | | 30-nm long external diameter | CLL infiltrate | |
| 15bis| Mesangial sclerosis and proliferation, capillary deposits, podocytosis | ND | CD20+ CD5+ CD23- CD10- C3 | ITGN | |
|      | Moderate polymorphic multifocal infiltrate | | | CLL infiltrate | |

MPGN, membranoproliferative glomerulonephritis; AHL, heavy- and light-chain amyloidosis; ITGN, immunotactoid/microtubular glomerulonephritis; ND, no data available.

MCD, minimal change disease; MPGN, membranoproliferative glomerulonephritis; ND, no data available.

doi:10.1371/journal.pone.0119156.t004
loops. Monotypic IgG lambda was found within the deposits, with endocapillary C3. The ultrastructural analysis revealed subendothelial organized microtubular deposits, characterized by a 30-nm long external diameter.

Two patients presented minimal change lesions, with normal light microscopy, normal immunofluorescence, and foot process effacement on the ultrastructural analysis (cases 7, 8). Patient 14 had glomerular heavy- and light-chain amyloidosis (AHL) related to a circulating IgG lambda monoclonal protein. Light microscopy found very large Congo red positive dichroic deposits in the mesangium, the subendothelial space of glomerular capillaries, Bowman’s capsule, the interstitium, the tubular basement membrane and the arterioles (Fig. 5). Immunofluorescence revealed an equally intense staining for gamma and lambda chains, and ultrastructural analysis showed that the deposits were composed by non-oriented 10-nm large fibers.

**Evolution**

The mean post-biopsy follow-up was 86 months (range 3–199 months) (Tables 6 and 7). All but 1 patient (case 7) received corticosteroids and/or cytotoxic treatment. Two patients with severe interstitial infiltration received methylprednisolone pulses followed by cytotoxic chemotherapy, with favorable renal outcomes (cases 2, 6).

Among the 7 patients presenting with NS and treated with cytotoxic agents, transient or persistent complete remission was observed in 5 patients. Partial remission was observed in patient 9 (MPGN), while patient 14 (AHL amyloidosis) had a persistent NS. In 4 patients with NS relapse observed during the follow-up, progression of the hematological malignancy was...

**Table 5. Kidney biopsy pathology.**

| Case  | Light microscopy                                      | Glomerular immunofluorescence | Infiltrate immunohistochemistry | Electron microscopy                           | Definite diagnosis                                      |
|-------|------------------------------------------------------|-------------------------------|---------------------------------|---------------------------------------------|--------------------------------------------------------|
| 11    | MPGN with endo- and extracapillary proliferation; Pseudo-thrombi; Severe monomorphic diffuse infiltrate | Ig gamma1 kappa C3, C1q traces | CD20+ CD5+ CD23 + CD10-        | Subendothelial granular and fibrillar deposits; No fibrillar organization in lymphocytes | Cryoglobulin-related MPGN CLL infiltrate               |
| 12    | MPGN; Pseudo-thrombi; Moderate monomorphic diffuse infiltrate | Ig gamma kappa C3             | CD20+ CD5+ CD23-CD10- Cyclin D1- | Cryoglobulin-related MPGN CLL infiltrate |                                                        |
| 12bis | MPGN; Pseudo-thrombi; Severe monomorphic diffuse infiltrate | Ig gamma kappa C3             | CD20+ CD5+ CD23-CD10- Cyclin D1- | Cryoglobulin-related MPGN CLL infiltrate |                                                        |
| 13    | MPGN appearance; Moderate monomorphic focal infiltrate | Ig gamma kappa C3             | ND                              | Endomembranous non-amyloid microfibrillar 8-nm diameter deposits | Fibrillar glomerulonephritis CLL infiltrate             |
| 14    | Amyloidosis; Mild polymorphic infiltrate; One interstitial granuloma | Ig gamma lambda               | CD20+ CD5- CD23-CD10- Cyclin D1- | Non-oriented multifocal 10-nm-large fibers | AHL Amyloidosis Granulomatous reaction                 |
| 15    | Mesangial sclerosis; One interstitial granuloma; Mild monomorphic focal infiltrate | Ig gamma lambda C3            | CD20+ CD5+ CD23- Cyclin D1-    | Subendothelial organized microtubular deposits; 30-nm long external diameter | ITGN; CLL Infiltrate Granulomatous reaction            |
| 15bis | Mesangial sclerosis and proliferation; Capillary deposits; Podocytosis; Moderate polymorphic multifocal infiltrate | ND                            | CD20+ CD5+ CD23-CD10- Cyclin D1- | ITGN; CLL infiltrate                                  |                                                        |

MPGN, membranoproliferative glomerulonephritis; AHL, heavy- and light-chain amyloidosis; ITGN, immunotactoid/microtubular glomerulonephritis; ND, no data available.

doi:10.1371/journal.pone.0119156.t005
also present. In 7/11 patients presenting with decreased eGFR at biopsy the eGFR increased after treatment. Four patients had a negative decline of eGFR after treatment, which occurred in the absence of hematological response (cases 5, 12bis, 14, 15bis). Five patients had a second kidney biopsy for relapse of NS or rapid decrease in eGFR. In all cases, the second kidney biopsy revealed progression of the renal lesions initially identified, with superimposed or increased interstitial infiltration in cases 5, 12, and 15.

At the last follow-up, progression of the kidney disease had required extrarenal suppleance therapy in 5 patients. Patient 6 needed transient hemodialysis, which was withdrawn after post-treatment recovery of kidney function. The mean plasma creatinine at the end of the follow-up, excluding the 5 patients requiring dialysis, was 122 micromol/l.

Discussion

This study attempted to better describe the spectrum of kidney pathology associated with CLL/SLL. The first occurrence of kidney disease in CLL was described in 1957 by Scott et al, in a
patient presenting with NS [14]. Subsequently, case reports and small series have underlined the diversity of lesions which may be found in CLL/SLL, including interstitial infiltration, immune-mediated glomerulonephritis, and drug toxicity. With the inclusion of 15 patients, the present study provides the largest series of all-cause kidney disease in CLL/SLL currently reported (Table 8). CLL is usually diagnosed in patients > 55 y (90%), with a sex ratio of 1.5 [15]. In this study the patients had a mean age 65.2 at the first kidney biopsy, younger than in the CLL/SLL general population (mean age 72), suggesting that complications due to kidney involvement can be diagnostic in CLL/SLL. Alternatively, patients with kidney disease could also present with more aggressive forms of CLL/SLL.

Renal interstitial infiltration is a frequent finding in autopsy series of CLL patients, estimated between 44 and 90% of patients. The B-cell infiltrate can either be nodular or diffuse, and its localization classically begins in the subcapsular cortex, at the corticomedullar junction, and along the vasa recta [16,17]. In our patients presenting with isolated infiltrates the lymphocytes were monotypic and presented a monomorphic, regular, and mature aspect, separating and directly infiltrating the tubular epithelium, surrounded by local accumulation of extracellular matrix. Usually, the infiltration of the kidneys by monoclonal B cells is bilateral, asymptomatic, and is diagnosed or suspected in late stages of the disease [18]. Even a massive infiltration of both kidneys can remain totally asymptomatic [5]. Urine sediment is usually normal, and proteinuria < 1 g/d. On the other hand, kidney infiltration can present as acute kidney failure or moderate chronic kidney disease [6,7,19,20]. In our study, although 10 patients presented a CLL/SLL-related infiltrate on kidney biopsy, only one patient had a typical enlargement of kidneys. The intensity of interstitial infiltration is usually correlated with the severity of kidney
failure, as suggested by the cases of several patients in our study (cases 2, 3, 5, 6) [16,21]. The mechanisms whereby the infiltrate may contribute to decrease GFR are not univocal, and in particular not limited to a mechanical compression [22]. Proinflammatory and profibrotic cytokines released by the infiltrating and/or resident cells could play an important role in tubulo-interstitial injury [23,24]. Accordingly, observational studies have shown that interstitial fibrosis was more frequent in areas of interstitial infiltration [16,21]. We found no clear association between the stage of CLL/SLL and the severity of renal failure, similar to a previous study [25]. The presence of extrarenal tumoral syndrome was generally associated with interstitial infiltration on the kidney biopsy. An important differential diagnosis for CLL/SLL-related interstitial infiltration is acute interstitial nephritis. The predominance of T cells, and/or the mixed lymphocyte population within interstitial aggregates which respect the normal parenchymal architecture are strong arguments against the diagnosis of CLL/SLL-related infiltration [21].
Interstitial granulomatous nephritis is found in less than 1% of native kidney biopsies, and 6–9% of biopsies revealing interstitial nephritis [26,27]. The most frequent causes of granulomas are infections, drug reactions, and inflammatory disorders, which were systematically excluded in the patients of the present study. In CLL/SLL, the presence of granulomas on kidney biopsy has been reported twice previously [4,28]. Granulomas are a relatively frequent finding in patients with Hodgkin’s lymphoma (14%), and non-Hodgkin’s lymphoma (7%), and are thought to be due to sarcoid reactions against tumor-derived antigens [29]. In this context, the activation of macrophages is typically mediated by T cells, which may explain the lower prevalence in B-cell malignancies. A series of 5 CLL/SLL patients with lymph node and bone marrow granulomas has been reported, which were related to mycobacteria or sarcoidosis, underlining the importance of excluding opportunistic infections in this context [30].

The association of glomerular disease in CLL/SLL has been reported in approximately 50 patients, mainly in case reports and in small cases series [31]. The most frequently reported lesions are MPGN (36%) and membranous nephropathy (19%), the latter frequently presenting with atypical characteristics such as proliferative lesions and monotypic deposits [31]. Less

---

Fig 4. GOMMID (case 15) (a) Light microscopy. Masson trichrome. Mesangial sclerosis with focal mesangial proliferation. Note mild monomorphic focal CLL/SLL infiltrate. Original magnification, X 10. (b) Light microscopy. Masson trichrome. Mesangial sclerosis and proliferation, capillary deposits. Original magnification, X 40. (c) Immunofluorescence microscopy. Monotypic Ig lambda deposits. The same fluorescence pattern was obtained with an anti-C3 antibody (data not shown). (d) Electron microscopy. Subendothelial organized microtubular deposits, 30-nm external diameter. Bar = 1200 nm.

doi:10.1371/journal.pone.0119156.g004
frequently, MCD, focal segmental glomerulosclerosis, amyloidosis, and immunotactoid/microtubular glomerulopathies may be found. A difficult issue in this context is to determine whether or not the glomerular injury is related to the hematologic malignancy. Classical criteria for paraneoplastic glomerulopathies include a chronological relation (GN often revealing the malignancy, or simultaneously diagnosed), a suspected pathophysiological link (such as dysproteinemia with or without cryoglobulinemia, cytokine-altered glomerular permeability, or T-cell dysregulation), and a parallel evolution of the malignancy and the glomerulopathy with specific cytotoxic treatment [32,33]. In our study, 6/15 patients presented a monoclonal dysproteinaemia, which is higher than reported in the general population of CLL patients [34,35]. The monoclonal protein secreted by the B-cell clone can either be directly involved in the pathogenesis of the lesions, as is the case in fibrillary glomerulopathy, immunotactoid/microtubular glomerulonephritis, AL amyloidosis, and type I/II cryoglobulinemia, or indirectly, as in cases of MPGN not related to cryoglobulinemia.

Fig 5. AHL amyloidosis (case 14) (a) Light microscopy. Masson trichrome staining. Massive amorphous deposits in the mesangium and extending to the subendothelial space of glomerular capillaries, Bowman's capsule, the interstitium, the tubular basement membrane and the arterioles. Original magnification, X20. (b) Apple green birefringence detected under polarized light. Original magnification, X20. (c) Immunofluorescence microscopy. Monotypic Ig lambda deposits. Equally intense staining for heavy and light chains. (d) Electron microscopy. Non oriented, randomly arranged, 10-nm diameter fibrils. Bar = 1250 nm.
MPGN is one of the most frequent kidney diseases described in association with CLL/SLL (Table 8). In our study, 5 patients presented a MPGN, including 2/5 without any detected dysproteinemia. Glomerular lesions associated with cryoglobulinemia are either due to immune complexes or to the direct targeting of native or planted glomerular antigens by the monoclonal cryoglobulin [8,36]. Irrespective of the mechanism leading to cryoglobulin deposition, glomerular infiltration by macrophages is frequent in this context and is believed to play an important pathogenic role [37]. Patient 13 presented a monotypic IgGκ fibrillary GN. The presentation of this patient was unusual since deposits in fibrillary GN are described as polytypic in 90% cases, and hypocomplementemia is rare [38,39]. In addition, fibrillary GN is exceptionally reported in CLL/SLL. Interestingly, Schneider et al reported a very similar case, suggesting an important role for complement activation in the pathogenesis of the glomerular lesions in this context [40]. As opposed to the glomerular lesions found in cryoglobulin-related MPGN, immunotactoid/microtubular glomerulonephritis is usually not associated with macrophage infiltration, thrombi or vasculitis-like lesions [38]. The microtubular deposits are monotypic, as in patient
15, their intensity being related to the quantity of the monoclonal component secreted by the B-cell clone [41]. The microtubular organization present in glomerular deposits can also be found in the Golgi apparatus of the malignant lymphocytes [41].

The literature describes 12 previous cases of CLL/SLL-related MCD [42–45]. The pathophysiology of this association is unclear. Both a disturbed pattern of cytokine production by the B clone and a T-cell dysfunction have been proposed. The parallelism between the evolution of the hematological disease and the podocytopathy before and after treatment strongly suggests an immune-mediated link involving the malignant clone.

Immunoglobulin-derived amyloidosis accounts for approximately 85% of amyloidosis diagnosed on kidney biopsy [46]. Few cases of CLL/SLL-related amyloidosis have been reported to date, despite the fact that up to 35% of CLL/SLL patients present abnormal serum free light chain ratios [47–51]. The reason for this theoretical discrepancy may be that the amount of circulating free light chains is usually moderate in CLL/SLL, and that CLL/SLL clones more frequently produce kappa than lambda light chains, lambda light chains typically being more amyloidogenic than kappa [50,51]. In our study one patient presented IgG lambda AHL.

Table 7. Post-biopsy follow-up and clinical course.

| Case | Treatment | Pcreat / MDRD eGFR before/post treatment | Proteinuria (g/d) before/post treatment | NS | Histology | Dialysis | CLL/SLL | Follow-up | Cause of death |
|------|-----------|-----------------------------------------|----------------------------------------|----|-----------|----------|---------|-----------|---------------|
| 11   | Chlorambucil Chlorambucil; Rituximab     | 168/66; 83/74                           | 14 / 0.19; 5.1 / <0.3                   | CR and relapse*; CR | N         | N        | Remission and relapse*; CR | 9 y Alive | /              |
| 12   | Chlorambucil                               | 536/180                                 | > 3 / 0.15                             | CR and relapse*     | Cryoglobulin-related MPGN | N        | Remission and relapse* | 8 y Deceased | Febrile medullary aplasia Acutisation CLL/ ESRD |
| 12bis| Chlorambucil Cys                           | 769/790                                 | 4.5 / Dialysis                         | Persistent           | N         | Y        | Progression               |          |                |
|      | CHOP                                     |                                        |                                        |                    |           |         |                        |          |                |
| 13   | Chlorambucil                               | 100/70                                  | > 6 / <0.3                             | CR                    | N         | N        | CR                     | 9 y Deceased | ND             |
| 14   | Alkeran Cys                                | 470/700                                 | 7 / Dialysis                           | Persistent           | N         | Y        | Stability               | 9 y Deceased | ND             |
| 15   | Chlorambucil; Chlorambucil; Fludarabine; Chlorambucil | 79/85                                  | 6.1 / < 0.3                           | CR and relapse; CR and relapse*; CR and relapse*; Persistent NS | ITGN CLL infiltrate | N        | Remission; Relapse*; Relapse*; Progression | 16 y Alive | /              |
| 15bis|Rituximab                                  | 530/300                                 | > 13 / Dialysis                        | PR                    | N         | Y        | Stability               |          |                |

Cs: corticosteroids; CHOP: cyclophosphamide+ adriamycin+ vincristine+ prednisone; R-FC: rituximab+ fludarabine+ cyclophosphamide; R-Bendamustine: rituximab+ bendamustine; Pcreat: Plasma creatinine (micromol/l); NS: nephrotic syndrome; CR: complete remission; PR: partial remission; ESRD: End Stage Renal Disease; MCD: minimal change disease; ITGN, immunotactoid/microtubular glomerulonephritis; Y; yes; N, no; ND, no data available.

*: Simultaneous relapses in NS and CLL/SLL

doi:10.1371/journal.pone.0119156.t007
amyloidosis, which is a particularly rare finding, AHL amyloidosis accounting for less than 5% of Ig-derived renal amyloidosis [46].

This study provides an overview of kidney diseases associated with CLL/SLL requiring biopsy due to decreased eGFR and/or NS. Undoubtedly, the clinical context leading to the indication of histological examination yields a bias in the results of this study. The comparison of our results with those of autopsy series strongly suggests that the prevalence of isolated CLL/SLL-related interstitial infiltration is underestimated in the present study. Inversely, the prevalence of immune-mediated glomerulonephritis is most probably overestimated, compared to the general population of CLL/SLL patients. Yet, we believe that this study provides a valuable overview of the renal lesions expected in CLL/SLL patients with a potential indication for kidney biopsy. Due to the broad spectrum of glomerular and interstitial diseases associated with CLL/SLL, and to the limits of clinicopathological correlations, kidney biopsy remains an essential tool in selected patients with decreased eGFR and/or NS. An important result of this study is that the conclusions of the kidney biopsy led to corticosteroid and/or cytotoxic treatment, and to subsequent favorable renal and hematological responses in a large number of patients.

Table 8. Previously reported series.

| Reference                | Patients | Tumoral | MPGN | MCD | Amyloidosis | Other proliferative GN | Interstitial granuloma | MN | Fibrillary GN | ITGN | MIDD | FSGS |
|--------------------------|----------|---------|------|-----|-------------|------------------------|------------------------|----|-------------|------|------|------|
| Present study            | n infiltrate | 15  | 10  | 5   | 2           | 1                      | 1                      | 5  | 1           | 1    |      |      |
| Moulin et al. 1992       |          | 13  | 6   | 8   | 1           |                        | 1                      | 2  | 1           | 1    |      |      |
| Kowalewska et al. 2011   |          | 7   | 7   | 2   | 2           | 1                      |                        | 1  | 1           |      |      |      |
| Seney et al. 1986        |          | 4   |     |     | 2           |                        |                        |    |             |      |      |      |
| Dabbs et al. 1986        |          | 12  | 1   | 2   | 5           |                        |                        |    |             |      |      |      |
| Da'as et al. 2001        |          | 3   | 1   |     |             |                        |                        |    |             |      |      |      |
| Hill et al. 2002         |          | 3   |     | 2   |             |                        |                        |    |             |      |      |      |
| Barbour et al. 2011      |          | 2   | 1   |     |             |                        |                        |    |             |      |      |      |
| Cameron et al. 1974      |          | 2   |     |     |             |                        |                        |    |             |      |      |      |
| Audart et al. 2008       |          | 2   | 1   | 1   |             |                        |                        |    |             |      |      |      |
| Sethi et al. 2010        |          | 2   |     | 2   |             |                        |                        |    |             |      |      |      |
| Sanchorawala et al. 2006 |          | 2   | 1   | 2   |             |                        |                        |    |             |      |      |      |
| Nasr et al. 2012         |          | 3   |     |     |             |                        |                        |    |             |      |      |      |
| Kourelis et al. 2013     |          | 4   |     |     |             |                        |                        |    |             |      |      |      |
| TOTAL                    |          | 74  | 25  | 21  | 8           | 8                      | 8                      | 5  | 4           | 4    | 4    | 2    |

MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis; MN, membranous nephropathy; MPGN, membranoproliferative glomerulonephritis; GN, glomerulonephritis; MIDD, monoclonal immunoglobulin deposition disease; DN, diabetic nephropathy; ITGN, immunotactoid/microtubular glomerulonephritis.

Single case reports published and not included in these case series are not presented in the Table.

doi:10.1371/journal.pone.0119156.t008
Acknowledgments

We thank Prof. Fabrice Jardin, Prof. Hervé Tilly, Dr. Aspasia Stamatoullas (hematology department, Centre Henri Becquerel, Rouen), Dr. Bernard Lenormand (hematology department, Rouen university hospital, Rouen), Dr. Assem Alrifai (hematology department, Evreux hospital, Evreux), Dr. Jean-Michel Picquenot (pathology department, Centre Henri Becquerel, Rouen), and Dr. Catherine Bessin, Dr. Olivier Drouineau, Dr. Stéphane Edet (nephrology department, Dieppe hospital, Dieppe), Dr. Pascal Seris (nephrology department, Croix-Rouge hospital, Bois Guillaume), Dr. Caroline Fréguin (nephrology department, Elbeuf-sur-Seine), and Dr. Frank Le Roy, Dr. Isabelle Etienne, Dr. Mélanie Hanoy, Dr. Dominique Bertrand (nephrology department, Rouen University Hospital, Rouen), for kindly providing access to the patients’ data.

Author Contributions

Conceived and designed the experiments: DG AF MG. Performed the experiments: ALP AF FD SL. Analyzed the data: ALP BLG BM MG DG. Contributed reagents/materials/analysis tools: SL BLG BM MG. Wrote the paper: ALP DG.

References

1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, et al. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446–5456. doi:10.1182/blood-2007-06-093906 PMID: 18216293

2. Muller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, et al. (2008) Chronic lymphocytic leukemia / small lymphocytic lymphoma. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon. pp. 180–182.

3. Uprety D, Peterson A, Shah BK, Dou X, Hu H, et al. (2013) Renal failure secondary to leukemic infiltration of kidneys in CLL—a case report and review of literature Concurrent nephrotic syndrome and acute renal failure caused by chronic lymphocytic leukemia (CLL): a case report and literature review. Ann Hematol 92: 271–273. doi:10.1007/s00277-012-1547-6 PMID: 22875063

4. Kamat AV, Goldsmith D, O'Donnell P, van der Walt J, Carr R (2007) Renal failure with granulomatous interstitial nephritis and diffuse leukemic renal infiltration in chronic lymphocytic leukemia. Ren Fail 29: 763–765. PMID:17763176

5. Da'as N, Polliack A, Cohen Y, Amir G, Darmon D, et al. (2001) Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol 67: 158–164. PMID:11737248

6. Phillips JK, Bass PS, Majumdar G, Davies DR, Jones NF, et al. (1993) Renal failure caused by leukemic infiltration in chronic lymphocytic leukaemia. J Clin Pathol 46: 1131–1133. PMID: 8298240

7. Haraldsottir V, Haanen C, Jordans JG (1992) Chronic lymphocytic leukaemia presenting as renal failure with lymphocytic infiltration of the kidneys. Neth J Med 41: 64–67. PMID:1407242

8. Moulin B, Ronco PM, Mougenot B, Francois A, Fillastre JP, et al. (1992) Glomerulonephritis in chronic lymphocytic leukemia and related B-cell lymphomas. Kidney Int 42: 127–135. PMID: 1635342

9. Seney FD Jr, Federgreen WR, Stein H, Kashgarian M (1986) A review of nephrotic syndrome associated with chronic lymphocytic leukemia. Arch Intern Med 146: 137–141. PMID: 3942445

10. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, et al. (1994) The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8: 1640–1645. PMID: 7523797

11. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney International Supplement 2: 139–274. PMID: 109299

12. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, et al. (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11: R31. PMID: 17331245

13. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplement 3: 1–150.
14. Scott RB (1957) Leukaemia. Lancet 272: 1162–1167. PMID: 13439992
15. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M (2011) Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22 Suppl 6: vi50–54. doi: 10.1093/annonc/mdr377 PMID: 21908504
16. Schwartz JB, Shamsuddin AM (1981) The effects of leukemic infiltrates in various organs in chronic lymphocytic leukemia. Hum Pathol 12: 432–440. PMID: 7250955
17. Noris HJ, Wiener J (1961) The renal lesions in leukemia. Am J Med Sci 241: 512–518. PMID: 13729602
18. Schwartz JB, Shamsuddin AM (1981) The effects of leukemic infiltrates in various organs in chronic lymphocytic leukemia. Hum Pathol 12: 432–440. PMID: 7250955
19. Noris HJ, Wiener J (1961) The renal lesions in leukemia. Am J Med Sci 241: 512–518. PMID: 13729602
20. Rockx MA, Rizkalla K, Clark WF (2008) Acute renal failure and chronic lymphocytic leukaemia. Nephrol Dial Transplant 23: 770–771. PMID: 17998226
21. Aymard B, Beghoura R, Molina TJ (2011) [Renal infiltrate by a plasmocytoid chronic B lymphocytic leukaemia and renal failure: a rare occurrence in nephropathology. A case report and review of the literature]. Nephrol Ther 7: 479–487. doi: 10.1016/j.nephro.2011.02.001 PMID: 21439927
22. Pagniez DC, Fenaux P, Delvallez L, Dequiedt P, Gosselin B, et al. (1988) Reversible renal failure due to specific infiltration in chronic lymphocytic leukemia. Am J Med 85: 579–580. PMID: 3177414
23. Hsu SM, Waldron JW Jr, Hsu PL, Hough AJ Jr (1993) Cytokines in malignant lymphomas: review and prospective evaluation. Hum Pathol 24: 1040–1057. PMID: 8406414
24. Lommatschzsch SE, Bellizzi AM, Cathro HP, Rosner MH (2006) Acute renal failure caused by renal infiltration by hematolymphoid malignancy. Ann Diagn Pathol 10: 230–234. PMID: 16844565
25. Inoue T, Sato T, Okada H, Kayano H, Watanabe Y, et al. (2010) Granulomatous interstitial nephritis in chronic lymphocytic leukaemia. Nephrol Dial Transplant 25: 4107–4109. doi:10.1093/ndt/gfq489 PMID: 20702535
26. Mignon F, Mery JP, Mougenot B, Ronco P, Roland J, et al. (1984) Granulomatous interstitial nephritis. Adv Nephrol Necker Hosp 13: 219–245. PMID: 6433667
27. Viero RM, Cavallo T (1995) Granulomatous interstitial nephritis. Hum Pathol 26: 1347–1353. PMID: 8522308
28. Inoue T, Sato T, Okada H, Kayano H, Watanabe Y, et al. (2010) Granulomatous interstitial nephritis in chronic lymphocytic leukaemia. Nephrol Dial Transplant 25: 4107–4109. doi:10.1093/ndt/gfq489 PMID: 20702535
29. Brincker H (1986) Sarcoid reactions in malignant tumours. Cancer Treat Rev 13: 147–156. PMID: 3536088
30. Brunner A, Kantner J, Tzankov A (2005) Granulomatous reactions cause symptoms or clinically imitate treatment resistance in small lymphocytic lymphoma/chronic lymphocytic leukaemia more frequently than in other non-Hodgkin lymphomas. J Clin Pathol 58: 815–819. PMID: 16049282
31. Moulin B, Chantrel F, Petitjean P, Ronco PM, Rosner MH (1995) Chronic lymphoproliferative disorders and glomerular diseases: review of the literature and pathophysiological considerations. J Nephrol 8: 20–26.
32. Cambier JF, Ronco P (2012) Onco-nephrology: glomerular diseases with cancer. Clin J Am Soc Nephrol 7: 1701–1712. doi: 10.2215/CJN.03770412 PMID: 22904123
33. Mailouk A, Pham PT, Pham PC (2006) Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies. Clin Exp Nephrol 10: 284–289. PMID: 17186334
34. Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, et al. (1991) B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. Blood 78: 1901–1914. PMID: 1912574
35. Hansen DA, Robbins BA, Blylund DJ, Piro LD, Saven A, et al. (1994) Identification of monoclonal immunoglobulins and quantitative immunoglobulin abnormalities in hairy cell leukemia and chronic lymphocytic leukemia. Am J Clin Pathol 102: 580–585. PMID: 7942620
36. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M (1974) Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57: 775–788. PMID: 4216269
37. Jacquot C, Nochy D, d’Auzac C, Durandy A, Reignier A, et al. (1987) Glomerulonephritis, B monoclonal small lymphocytic lymphoma and mixed cryoglobulinemia. Clin Nephrol 27: 263–268. PMID: 3297440
38. Touchard G, Bridoux F, Goujon JM (2005) Glomerulonephritis with organized immunoglobulin deposits. Nephrol Ther 1: 355–364. PMID: 16895706

39. Bridoux F, Hugue V, Coldefy O, Goujon JM, Bauwens M, et al. (2002) Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int 62: 1764–1775. PMID: 12371978

40. Schneider R, Lugassy G, Schlesinger M, Kopolovic J, Yagil Y (1996) Fibrillar glomerulopathy associated with chronic lymphocytic leukaemia. Nephrol Dial Transplant 11: 1352–1355. PMID: 8672038

41. Touchard G, Bauwens M, Goujon JM, Aucouturier P, Patte D, et al. (1994) Glomerulonephritis with organized microtubular monoclonal immunoglobulin deposits. Adv Nephrol Necker Hosp 23: 149–175. PMID: 8154350

42. Alzamora MG, Schmidli M, Hess U, Cathomas R, von Moos R (2006) Minimal change glomerulonephritis in chronic lymphocytic leukemia: pathophysiological and therapeutic aspects. Onkologie 29: 153–156. PMID: 16601371

43. Kowalewska J, Nicosia RF, Smith KD, Kats A, Alpers CE (2011) Patterns of glomerular injury in kidneys infiltrated by lymphoplasmacytic neoplasms. Hum Pathol 42: 896–903. doi: 10.1016/j.humpath.2010.09.009 PMID: 21288559

44. Dabbs DJ, Striker LM, Mignon F, Striker G (1986) Glomerular lesions in lymphomas and leukemias. Am J Med 80: 63–70. PMID: 3510541

45. Vivaldi P, Frizzi R, Rovati C, Pedrazzoli M (1992) Nephrotic syndrome in chronic lymphocytic leukemia. Haematologica 77: 438–439. PMID: 1483598

46. Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, et al. (2013) Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 8: 1515–1523. doi: 10.2215/CJN.10491012 PMID: 23704299

47. Ikee R, Kobayashi S, Hemmi N, Suzuki S, Miura S (2005) Amyloidosis associated with chronic lymphocytic leukemia. Amyloid 12: 131–134. PMID: 16011991

48. Sanchorawala V, Blanchard E, Seldin DC, O’Hara C, Skinner M, et al. (2006) AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes. Am J Hematol 81: 692–695. PMID: 16795060

49. Dou X, Hu H, Ju Y, Liu Y, Kang K, et al. (2011) Concurrent nephrotic syndrome and acute renal failure caused by chronic lymphocytic leukemia (CLL): a case report and literature review. Diagn Pathol 6: 99. doi: 10.1186/1746-1596-6-99 PMID: 21995711

50. Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, et al. (2013) Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 88: 375–378. doi: 10.1002/ajh.23413 PMID: 23508840

51. Dispenzieri A, Gertz MA, Buadi F (2012) What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev 26: 137–154. doi: 10.1016/j.bire.2012.03.001 PMID: 22937397